The Frontiers Research Topics : MEDICIS-Promed, Advances in Radioactive Ion Beams for Nuclear Medicine is now published. It can be downloaded from there.
The half-life of Tb-155 produced at MEDICIS has been revised and is now published by S. Collins et al. in Applied Radiation and Isotope. High molar activity Sm-153 was 1st used in Targeted Radionuclide Therapy and theranostics (MED-025) by M. Ooms et al, as presented at TERACHEM.
A third collaboration meeting took place today in the French ANR project REPARE, to review the progresses on the development of a high power Bi target for the production of At-211.
1st projects have been selected in PRISMAP-The European medical isotope programme.
- tenure-track position in the superheavy element chemistry department at GSI Darmstadt, Germany. 13/11/22. Prof. C.E. Duellman.
- PSI-FELLOW-III-3i / Postdoctoral Fellows (f/m/d) : R&D of laser ionization and mass separation for ISOL radionuclide production (IMPACT facility initiative, https://www.psi.ch/en/impact), to be extended [ into a tenure-track permanent scientist position for TATTOOS in 2025 psi-fellow-fmd, 30/11/22 24:00 CET. Contacts Nick van der Meulen.
A KNOWLEDGE TRANSFER SUCCESS STORY
GRANTS & DONATIONS - CERN & Society Foundation
The CERN KT-Fund
La Fondation pour l'innovation sur le cancer et la biologie
The ADAM company